Phase 1 study of SurVaxM™ in survivin-positive NETs
Researcher: Renuka Iyer, MD Location: Roswell Park Comprehensive Cancer Center State: New York Year: 2018 Status: Active Grant Duration: 1 year Award: Pilot Award
Leave it blank
This study tests the immunotherapy SurVaxM in combination with a somatostatin analog in patients with survivin-expressing NETs. The vaccine targets survivin, a protein that’s often highly expressed in lung, intestinal, and pancreatic NETs and associated with aggressive disease because of its ability to prevent tumor cell death. Many patients with incurable brain cancers on SurvaxM have shown better outcomes than would be expected with standard of care alone.
NET Research Foundation
321 Columbus Avenue, Suite 5R
Boston MA 02116